Sarepta Therapeutics, Inc. (BMV:SRPT)

Market Cap	73.68B
Revenue (ttm)	45.65B
Net Income (ttm)	-5.08B
Shares Out	n/a
EPS (ttm)	-52.93
PE Ratio	n/a
Forward PE	6.62
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,538
Average Volume	541
Open	818.65
Previous Close	701.95
Day's Range	801.27 - 818.65
52-Week Range	700.00 - 2,501.45
Beta	n/a
RSI	20.66
Earnings Date	May 6, 2025

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 1,372
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: SRPT

Financial Performance

Financial numbers in USD